©The Author(s) 2025.
World J Clin Oncol. Nov 24, 2025; 16(11): 111983
Published online Nov 24, 2025. doi: 10.5306/wjco.v16.i11.111983
Published online Nov 24, 2025. doi: 10.5306/wjco.v16.i11.111983
Table 4 Blast crisis chronic myeloid leukemia clusters integrating mutation biology and therapeutic guidance
| Cluster | Key mutations | Catalogue of Somatic Mutations in Cancer signatures | Processes | Drugs |
| Cluster 1 | Breast cancer susceptibility gene 2, TP53 | S3, S5 | Homologous recombination deficiency | Olaparib, nutlin-3 |
| Cluster 2 | Isocitrate dehydrogenase 1/2, ten-eleven translocation 2 | S1, S2 | Methylation shift | Ivosidenib, azacitidine |
| Cluster 3 | Janus kinase 2, colony-stimulating factor 3 receptor | S13, S18 | Inflammation, reactive oxygen species | Ruxolitinib, N-acetylcysteine |
- Citation: AlGarni A, Alanazi N, AlMukhaylid S, Alqahtani S, Almasoudi H, Samir Taleb Y, Alkhamis N, Shaheen S, Haji Siyal A, Aleem A, Naeem R, Shammas MA, Saglio G, Alroweilly D, Hussain A, Iqbal Z. Omics and artificial intelligence integration for stratifying blast crisis CML using COSMIC signatures and pan-cancer precision drug repurposing. World J Clin Oncol 2025; 16(11): 111983
- URL: https://www.wjgnet.com/2218-4333/full/v16/i11/111983.htm
- DOI: https://dx.doi.org/10.5306/wjco.v16.i11.111983